drugset / Trial / NCT07100691

Gastric Emptying With Metoclopramide in GLP-1 Agonist Patients Undergoing Elective Surgery

NCT07100691

Phase 4 Not yet recruiting 80 enrolled Mater Misericordiae University Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a multicentre, investigator-blinded, randomised controlled trial evaluating whether the use of oral metoclopramide before surgery can reduce the amount of residual gastric content in patients who are taking glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight loss. These medications are known to slow down gastric emptying, which may increase the risk of pulmonary aspiration during anaesthesia. Patients will be randomly assigned to either receive metoclopramide 24 hours before surgery or continue with standard care. The primary outcome will be the presence or absence of residual gastric content on ultrasound before surgery. Secondary outcomes include nausea, vomiting, constipation, and any adverse effects of the medication.

Timeline

Start
2025-08
Primary completion
2026-05
Completion
2026-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Metoclopramide Small molecule 10 mg Oral

Indications